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Numerous kindreds with familial frontotemporal dementia and/or amyotrophic lateral sclerosis have been linked to chromosome
9, and an expansion of the GGGGCC hexanucleotide repeat in the non-coding region of chromosome 9 open reading frame 72
has recently been identiﬁed as the pathogenic mechanism. We describe the key characteristics in the probands and their affected
relatives who have been evaluated at Mayo Clinic Rochester or Mayo Clinic Florida in whom the hexanucleotide repeat ex-
pansion were found. Forty-three probands and 10 of their affected relatives with DNA available (total 53 subjects) were shown
to carry the hexanucleotide repeat expansion. Thirty-six (84%) of the 43 probands had a familial disorder, whereas seven (16%)
appeared to be sporadic. Among examined subjects from the 43 families (n = 63), the age of onset ranged from 33 to 72 years
(median 52 years) and survival ranged from 1 to 17 years, with the age of onset 540 years in six (10%) and 460 in 19 (30%).
Clinical diagnoses among examined subjects included behavioural variant frontotemporal dementia with or without parkinson-
ism (n = 30), amyotrophic lateral sclerosis (n = 18), frontotemporal dementia/amyotrophic lateral sclerosis with or without
parkinsonism (n = 12), and other various syndromes (n = 3). Parkinsonism was present in 35% of examined subjects, all of
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inant clinical phenotype. No subject with a diagnosis of primary progressive aphasia was identiﬁed with this mutation.
Incomplete penetrance was suggested in two kindreds, and the youngest generation had signiﬁcantly earlier age of onset
(410 years) compared with the next oldest generation in 11 kindreds. Neuropsychological testing showed a proﬁle of
slowed processing speed, complex attention/executive dysfunction, and impairment in rapid word retrieval. Neuroimaging
studies showed bilateral frontal abnormalities most consistently, with more variable degrees of parietal with or without
temporal changes; no case had strikingly focal or asymmetric ﬁndings. Neuropathological examination of 14 patients revealed
a range of transactive response DNA binding protein molecular weight 43 pathology (10 type A and four type B), as well as
ubiquitin-positive cerebellar granular neuron inclusions in all but one case. Motor neuron degeneration was detected in nine
patients, including ﬁve patients without ante-mortem signs of motor neuron disease. While variability exists, most cases with
this mutation have a characteristic spectrum of demographic, clinical, neuropsychological, neuroimaging and especially
neuropathological ﬁndings.
Keywords: frontotemporal dementia; amyotrophic lateral sclerosis; motor neuron disease; TDP-43; neurogenetics; chromosome 9
Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration;
MND = motor neuron disease; SPECT = single photon emission computed tomography; TDP-43 = Transactive response DNA binding
protein molecular weight 43
Introduction
Familial frontotemporal dementia (FTD) with or without parkinson-
ism has been associated with mutations in genes encoding microtu-
bule associated protein tau (MAPT), progranulin (PGRN), and less
commonly valosin-containing protein, TAR DNA-binding protein
(TDP) and fused in sarcoma (FUS) while familial amyotrophic lateral
sclerosis (ALS)has beenassociated withmutations in genesencoding
Cu/Zn superoxide dismutare-1, TDP and FUS (Rosen et al., 1993;
Huttonetal.,1998;Wattsetal.,2004;Bakeretal.,2006;Crutsetal.,
2006; Kabashi et al., 2008; Sreedharan et al., 2008; Kwiatkowski
et al., 2009; Vance et al., 2009). The phenotype of familial
FTD and/or ALS has been linked to chromosome 9 (Morita et al.,
2006; Vance et al., 2006; Valdmanis et al., 2007; Luty et al., 2008;
Le Ber etal., 2009; Gijselinck et al., 2010; Boxer et al., 2011; Pearson
et al., 2011), and while the identiﬁcation of the pathogenic genetic
mutation has been challenging to identify, the cause of the disease in
these families was recently discovered in our index family known as
theVancouver–SanFrancisco–MayoClinicFamily20andmanyother
families (Boxer et al., 2011; DeJesus-Hernandez et al., 2011; Renton
et al., 2011). The mutation is an expansion of the GGGGCC hexanu-
cleotide repeat in the non-coding intronic region of the chromosome
9 open reading frame 72 gene (C9ORF72) (DeJesus-Hernandez
et al., 2011; Renton et al., 2011), and the disease is known as FTD
and/or ALS linked to chromosome 9 (c9FTD/ALS) (DeJesus-
Hernandez et al., 2011; Murray et al., 2011). The ante-mortem clin-
ical features of affected individuals remain to be reported, but there
are already reports of pathological features of c9FTD/ALS due to
C9ORF72 mutations (Al-Sarraj et al., 2011; Murray et al., 2011). In
this report, we describe demographic, clinical, neuropsychological,
neuroimaging and neuropathological ﬁndings in a large series of in-
dividuals ascertained from the Mayo Clinics in Minnesota and Florida
in whom this repeat expansion was found, either in them or their
affected relatives.
Materials and methods
Subjects
The GGGGCC hexanucleotide repeat in C9ORF72 was screened for in
all subjects with FTD or primary progressive aphasia in the Mayo Clinic
Alzheimer Disease Research Centre database (n = 177 in Mayo Clinic
Rochester, n = 197 in Mayo Clinic Florida), Mayo Clinic Alzheimer’s
Disease Patient Registry database (n = 1), and in subjects with ALS in
the Mayo Clinic Florida Amyotrophic Lateral Sclerosis database
(n = 229) (DeJesus-Hernandez et al., 2011). At least one affected in-
dividual from each family and all sporadic cases were enrolled in one
of these research programmes, each of which is a Mayo Foundation
Institutional Review Board-approved programme. All available clinical
records, neuropsychological data, neuroimaging studies and patho-
logical examinations on affected members of these kindreds were re-
viewed. Genetic analyses, clinical assessments, neuropsychological
assessments, neuroimaging studies and autopsies were performed
after subjects and/or appropriate proxies provided written consent.
Clinical cohorts
One proband was recruited and followed in the Alzheimer’s Disease
Patient Registry programme, which focused on subjects residing in
Olmsted County, Minnesota, and once the FTD phenotype and famil-
ial nature of the disorder was appreciated, other relatives were re-
cruited and followed longitudinally. The Mayo Clinic Rochester
clinical cohort includes all cases with an FTD or primary progressive
aphasia diagnosis regardless of family history, who were enrolled in
the Mayo Clinic Alzheimer’s Disease Research Centre or Alzheimer’s
Disease Patient Registry programmes from 1986 to 2011; since recruit-
ment of familial FTD has been a focus of interest for many years, this
cohort was expected to have a higher frequency of familial cases. The
Mayo Clinic Florida Alzheimer’s Disease Research Centre clinical cohort
includes all cases with an FTD or primary progressive aphasia diagnosis
regardless of family history who were enrolled from 1990 to 2011. The
Mayo Clinic Florida ALS cohort includes all cases with ALS, regardless
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The available information on each case with a diagnosis of FTD or
primary progressive aphasia was reassessed to determine how each
would be classiﬁed using the updated behavioural variant FTD
(Rascovsky et al., 2011) and primary progressive aphasia
(Gorno-Tempini et al., 2011) subtype criteria [almost all cases had
been previously classiﬁed by the Neary et al. (1998) criteria]. Each
case previously classiﬁed as FTD indeed met criteria for the behavioural
variant FTD diagnosis, and DNA on all available cases were genotyped.
Among the reclassiﬁed cases with primary progressive aphasia, only
cases with the non-ﬂuent/agrammatic and semantic subtypes were
included in the DNA screen; since most with the logopenic subtype
likely have underlying Alzheimer’s disease, they were excluded from
this screen. Subjects classiﬁed with the primary diagnoses of mild cog-
nitive impairment, Alzheimer’s disease, dementia with Lewy bodies,
corticobasal syndrome, progressive supranuclear palsy and posterior
cortical atrophy were also excluded from the DNA screen for purposes
of this initial analysis focused on cases with FTD, primary progressive
aphasia and/or ALS.
Subjects were classiﬁed as being familial (the presence of a positive
family history) or sporadic based on speciﬁc sets of criteria. For sub-
jects with a dementia syndrome as the major phenotype, a positive
family history was deﬁned as a ﬁrst- or second-degree relative with
FTD and/or ALS or a ﬁrst-degree relative with memory problems, be-
havioural changes, parkinsonism or another suspected neurodegenera-
tive disorder. A positive family history in the Mayo Clinic Florida ALS
series was deﬁned as a ﬁrst- or second-degree relative with ALS (Byrne
et al., 2011). Since the published criteria for determining familial ALS
does not consider a family history of dementia or parkinsonism (Byrne
et al., 2011), a looser deﬁnition of positive family history was also
used, in which the presence of one or more ﬁrst- or second-degree
relatives with dementia, parkinsonism or ALS was also used in fre-
quency calculations, with the strict deﬁnition of sporadic disease
being the absence of any ﬁrst or second-degree relatives with demen-
tia, parkinsonism or ALS.
Clinical features and diagnoses
Age of onset for dementia was the age at which the subject ﬁrst
demonstrated behavioural/personality, cognitive  parkinsonism as
noted by themselves, their relatives or their clinicians. Age of onset
for ALS was the age at which any symptom reﬂecting upper motor
neuron and/or lower motor neuron dysfunction was noted by them-
selves, their relatives, or their clinicians. Survival (in years) was based
on the number of years from onset of any neurological symptoms to
death. All neurological clinical data (Members of the Department of
Neurology, 1998) were reviewed. The presence or absence of the
following clinical features were recorded: personality/behaviour
changes (self explanatory), executive dysfunction (deﬁned as impair-
ment in sustained attention, multi-tasking, decision-making, problem
solving, etc.), memory impairment (deﬁned as forgetfulness for details
of recent events or upcoming plans and poor delayed word list recall),
aphasia (deﬁned as difﬁculties with object or person naming, or recep-
tive or expressive language functioning), parkinsonism (deﬁned as
some combination of masked facies, stooped posture, shufﬂing gait,
rest tremor, bradykinesia, rigidity, postural instability), frontal release
signs (deﬁned as grasp, snout or palmomental reﬂex present), and
pseudobulbar affect (deﬁned as the tendency to cry or laugh inappro-
priately). Features of upper motor neuron and lower motor neuron
dysfunction were considered present when speciﬁcally recorded in
the clinical record, and were subclassiﬁed based on the level of
involvement. The upper motor neuron features were characterized as
follows: bulbar—pseudobulbar affect, snout or palmomental reﬂex,
exaggerated jaw jerk, spastic dysarthria; cervical—hyper-reﬂexia
and/or spasticity in the upper limbs, Hoffmann sign present; thor-
acic—absent superﬁcial abdominal reﬂex; lumbar—hyper-reﬂexia
and/or spasticity in the lower limbs, crossed adductor reﬂex, Babinski
sign present. The lower motor neuron features were characterized as
follows: bulbar—facial or tongue fasciculations, muscle wasting, and
weakness, ﬂaccid dysarthria; cervical—upper limb fasciculations,
muscle wasting and weakness; thoracic—trunk or abdominal fascicu-
lations, muscle wasting and weakness; lumbar—lower limb fascicula-
tions, muscle wasting and weakness.
Clinical diagnoses were based on published criteria for FTD, progres-
sive non-ﬂuent aphasia, semantic dementia, ALS, etc. (Neary et al.,
1998; Brooks et al., 2000), and as noted above, each case was reclas-
siﬁed using the updated behavioural variant FTD and primary progres-
sive aphasia criteria (Gorno-Tempini et al., 2011; Rascovsky et al.,
2011). Patients with ALS were classiﬁed as ‘clinically deﬁnite’, ‘prob-
able’, ‘probable lab-supported’, ‘possible’ or ‘suspected’ ALS according
to the El Escorial criteria, allowing for concomitant presence of signs of
FTD in patients with FTD and ALS (Brooks et al., 2000). The site of
onset—bulbar, upper and lower spinal level—was also noted based on
available historical and clinical data for each case. Those who under-
went electromyography were noted as such. The diagnosis of com-
bined FTD/ALS was based on the presence of both FTD and ALS
features. Those that had some combination of masked facies, stooped
posture, shufﬂing gait, rest tremor, bradykinesia, rigidity, postural in-
stability, etc. were characterized as having parkinsonism based on
examination or informant report; the clinical diagnosis of Parkinson’s
disease was reserved for those who were formally examined and had
the cardinal features based on published criteria (Hughes et al., 1992).
Those that had a dementing illness characterized by an insidious onset
and progressive course, but were either examined in the late stage of
the illness or whose characterization was based on informant report
alone, were labelled as having dementia. The designation of ‘clinically
deﬁnite’ behavioural variant FTD, ALS, parkinsonism, or some combin-
ation of these, was reserved for only those subjects who were person-
ally examined by one or more of the co-authors.
Since recent data suggest that psychosis and altered eating
behaviour are associated with FTD/ALS and/or TAR DNA binding
protein molecular weight 43 (TDP-43) pathology (Lillo et al., 2010;
Burrell et al., 2011; Piguet et al., 2011), the presence or absence of
these features was also sought by reviewing the available clinical
records.
Laboratory analyses
Genomic DNA was extracted from peripheral blood samples using
standard procedures. For each subject, genomic DNA was screened
for the presence of the expanded hexanucleotide repeat in
C9ORF72 using the repeat primed polymerase chain reaction
method as previously described (DeJesus-Hernandez et al., 2011). In
short, polymerase chain reaction was performed with 100ng/mlo f
genomic DNA in the presence of 1 M betaine (Sigma), 5% dimethyl
sulphoxide (Sigma), 5mM of dCTP, dATP, dTTP (Promega) and
7-deaza-2-deoxy GTP (Roche) in substitution for dGTP. The cycling
programme included an initial denaturation at 98C for 10min fol-
lowed by 10 cycles of denaturation at 97C for 35s, annealing at
64C for 2min and extension at 68C for 8min, followed by
25 cycles of denaturation at 97C for 35s, annealing at 64C for
2min and extension at 68C for 8min plus an additional 20s for
each cycle.
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A battery of neuropsychological tests was available for 27 subjects.
Four additional subjects were deemed too impaired to complete a
full battery and their evaluation was limited to one or more cognitive
screening exams, including the Mini-Mental State Examination
(Folstein et al., 1975), Dementia Rating Scale-2 (Mattis, 1988) or
ALS-Cognitive Behavioural Screen (Woolley et al., 2010). Some sub-
jects who completed the neuropsychological battery also completed
one or more screening exams.
The neuropsychological battery included tests of attention and ex-
ecutive functioning [Digit Span (n = 14) (Wechsler, 1981, 1997a), Trail
Making Test (n = 20) (Reitan, 1958) and Stroop Colour-Word Test
(n = 12) (Golden, 1978)]; language [Boston Naming Test (n = 25)
(Kaplan et al., 1983), Controlled Oral Word Association Test
(n = 21) (Benton et al., 1994), and semantic/category ﬂuency for ani-
mals, fruits and vegetables (n = 21)]; learning and memory [delayed
recall from Logical Memory (n = 22) (Wechsler, 1987, 1997b), Visual
Reproduction (n = 19) (Wechsler, 1987, 1997b) and Auditory Verbal
Learning Test (n = 20) (Rey, 1964) or California Verbal Learning Test-II
(n = 4) (Delis et al., 2000)], visuospatial skills [Block Design (n = 13)
(Wechsler, 1981, 1997a) and Judgement of Line Orientation (n = 11)
(Benton et al., 1994)], and estimated premorbid functioning [Reading
subtest from the Wide Range Achievement Test, 3rd edition (n = 17)
(Wilkinson, 1993)]. Age-corrected normative data were obtained from
the Mayo Older American Normative Studies (Ivnik et al., 1992, 1996,
1997; Lucas et al., 1998a, b) and published test manuals. To minimize
variability due to normative reference sources, the youngest Mayo
Older American Normative Studies age bracket was extended down-
ward to include subjects aged 50–55 years. Normative data for adults
aged 550 years were derived separately for the Trail Making Test
(n = 2) (Bornstein, 1985), Boston Naming Test (n = 4) (Tombaugh
and Hubley, 1997), and Judgement of Line Orientation (n =1 )
(Benton, 1994). Cognitive impairment was deﬁned as test scores 1.5
standard deviations below the respective normative group mean.
Neuroimaging examinations
Magnetic resonance imaging
MRIs were performed either at 1.5 or 3 tesla (GE Healthcare). At 1.5
tesla, a 3D spoiled gradient recalled acquisition in steady state (SPGR)
and at 3 tesla a magnetization prepared rapid gradient echo acquisi-
tion (MPRAGE) were performed for the assessment of grey matter
atrophy. A ﬂuid attenuated inversion recovery (FLAIR) sequence was
performed at both 1.5 and 3 tesla. To visualize the patterns of grey
matter atrophy in individual subjects, we created Z-score maps or
STAND-Maps (STructural Abnormality due to NeuroDegeneration-
Maps), which indicate the atrophy in terms of Z-scores relative to a
group of cognitively normal controls in 120 brain regions (Vemuri
et al., 2011).
Single photon emission computed tomography
Brain single photon emission computed tomography (SPECT) using
Tc-99m-ECD (Neurolite) as the radiotracer was performed on select
cases, as was brain PET using ﬂuorodeoxyglucose (FDG) as the radio-
tracer, and the patterns of hypoperfusion (for SPECT) and hypometa-
bolism (for PET) were noted.
In the SPECT acquisition protocol, 20mCi of Tc-99m-ECD
(Neurolite) were injected intravenously. Images were acquired on a
dual-headed Elscint Helix gamma camera system (Elscint Inc.) with
ultra-high-resolution fan beam collimators. Standard vendor acquisition
and reconstruction parameters were used. These images were con-
verted to Analyse format (Biomedical Imaging Resource, Mayo
Foundation) for further processing including normalization, smoothing
and segmentation, which was performed with SPM5. A two-sample
t-test between subjects with C9ORF72 hexanucleotide repeat expan-
sion and the control group was performed in SPM5 (Ashburner and
Friston, 2005) with age and gender entered as nuisance covariates
(uncorrected P50.05).
Given the largest difference between the groups in this analysis was
in the cingulate cortex, we extracted the mean relative SPECT intensity
within a cingulate region of interest for each SPECT scan. The cingu-
late region of interest is a combination of bilateral anterior and middle
cingulate regions of the automated anatomic labelling atlas
(Tzourio-Mazoyer et al., 2002).
An image of the salience network was derived from a high-
dimensional group independent component analysis of resting state
functional MRI data from 893 subjects from the Mayo Clinic
Study of Ageing (Roberts et al., 2008). The topography of the salience
network was compared with the topography of hypoperfusion on
SPECT.
Positron emission tomography
For FDG-PET, subjects were injected with ﬂuorodeoxyglucose (370–
555 MBq range), in a dimly lit room with minimal auditory stimulation.
Standard acquisition and vendor reconstruction parameters were used.
FDG-PET scans were processed using CortexID software (GE Medical).
The activity in each subject’s PET data set was normalized to the pons
and compared with an age-segmented normative database, yielding
Z-score 3D-SSP images.
Neuropathological examination and
diagnosis
Archival material was available for neuropathological examination for
14 cases. Haematoxylin and eosin stains were used to examine neur-
onal loss and gliosis in cortical, limbic, basal ganglia and brainstem
structures. Luxol fast blue stains were available on medulla or spinal
cord (n = 9), or both, supplemented by neuroﬁlament or microglial
immunohistochemistry in some cases, for assessment of corticospinal
tract degeneration using methods previously described (Murray et al.,
2011). In some cases, only haematoxylin and eosin material was avail-
able. Bielschowsky silver stains or thioﬂavin S ﬂuorescent microscopy
were used to assess Alzheimer type pathology and both a CERAD
neuritic plaque score (Mirra et al., 1991) and a Braak neuroﬁbrillary
tangle stage (Braak and Braak, 1991) was assigned to each case.
Midbrain and amygdala sections were examined for Lewy-related
pathology with immunohistochemistry using a monoclonal antibody
to -synuclein (n = 10, LB509, 1:100, Zymed). Immunohistochemistry
for phospho-TDP-43 was available on all but one case (a 1967 case
from tissue archives) with a sensitive and speciﬁc antibody (ps409/
410, 1:5000, Cosmobio Co.). Almost all cases also had immunohisto-
chemistry for ubiquitin with a sensitive and speciﬁc monoclonal anti-
body (MAB1510, 1:60000; Chemicon). Presence of cerebellar granular
neuron inclusions was assessed in all 14 cases and scored based upon
the density of inclusions as: 0 = absent, 1 = sparse, 2 = moderate and
3 = frequent.
Microscopic pathology methods for cortical degeneration, substantia
nigra degeneration, lower motor neuron loss and evaluation of hippo-
campal sclerosis have been previously described (Murray et al., 2011).
Lower motor neuron degeneration was assessed in hypoglossal nucleus
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and gliosis, as well as presence of inclusions on haematoxylin and
eosin stains (Lewy body-like hyaline inclusions and Bunina bodies)
and on TDP-43 immunohistochemistry (skein-like inclusions).
Neuropathological diagnosis of frontotemporal lobar degeneration
with TDP-43 positive inclusions (FTLD-TDP) was made if there was
neuronal loss and gliosis affecting frontal or temporal lobe with
ubiquitin-positive or TDP-43-positive neuronal inclusions in cortical
and subcortical regions (Josephs et al., 2009). Cases were subtyped
using the classiﬁcation scheme of Mackenzie et al. (2006) as validated
for subcortical brain regions (Josephs et al., 2009) and also assigned a
recently recommended ‘harmonized’ type (Mackenzie et al., 2011).
A neuropathological diagnosis of FTLD with motor neuron disease
(MND) was made if there were ﬁndings of FTLD-TDP as well as evi-
dence of motor neuron loss and neuronal inclusions with variable
corticospinal tract degeneration (Josephs et al., 2006).
Results
Genetic/inheritance ﬁndings
In our largest and conclusively chromosome 9p-linked FTD/ALS
kindred (Vancouver–San Francisco–Mayo Clinic Family 20) which
was recently described (Boxer et al., 2011), the disease was asso-
ciated with an expansion of the non-coding GGGGCC hexanu-
cleotide repeat in C9ORF72 (DeJesus-Hernandez et al., 2011).
All cases in our three cohorts were then screened for this expan-
sion, with frequencies of expansion detected shown in Table 1.
The frequency of expansion varied from 3.6% to 11.2% among
all screened cases, and from 6.3% to 38.2% among cases with a
positive family history. Note that the frequency data vary depend-
ing on how strictly the deﬁnition for positive family history is
applied in the ALS cohort.
The frequency of the C9ORF72 expansion based on the clinical
phenotype is shown in Table 2. The frequency of the expansion
among all screened cases was highest in those with FTD/ALS
(21.6%), and among cases with a positive family history, the fre-
quency was highest in FTD/ALS (47.6%). Sporadic cases in all
three phenotypes had the expansion detected, but these were
uncommon (55% in each group). Table 2 also shows the fre-
quency of mutations in MAPT and PGRN in these three pheno-
types; mutations in these genes were only identiﬁed in the
behavioural variant FTD phenotype. Among cases with behaviour-
al variant FTD with a positive family history, the frequencies of
mutations in these two genes (12.7% for MAPT and 6.8% for
PGRN) were slightly lower than the frequency of the C9ORF72
mutation (14.7%). Among the cases with familial ALS, the fre-
quency of the C9ORF72 mutation (24%) was similar to the com-
bination of three other genes (24%). These data therefore indicate
that a sizable proportion of cases with familial FTD/ALS are now
explained by the C9ORF72 mutation.
In addition to the proband in the Vancouver–San Francisco–
Mayo Clinic Family 20 kindred, the repeat expansion was identi-
ﬁed in 42 other probands with either sporadic (n = 7) or familial
(n = 35) behavioural variant FTD, ALS or FTD/ALS, and in an add-
itional 10 affected relatives (totalling 53 cases). Ten additional af-
fected relatives were examined but did not have DNA available for
analysis (total 63 examined cases). Clinical records were available
for 40 additional relatives with dementia, parkinsonism or ALS,
and data on the total of 103 cases were analysed for demographic
analyses, realizing that some of these cases could have been
phenocopies.
As shown in Table 3, the majority of kindreds (84%) were fa-
milial, demonstrating an autosomal dominant pattern of inherit-
ance. Approximately 33% had dementia or behavioural variant
FTD as the only phenotype expressed in the family, while 3%
had only ALS expressed in the family. More than half (58%)
had both behavioural variant FTD and ALS expressed in affected
members of the kindred. Seven (16%) had no apparent
family history of neurodegenerative disease. Two kindreds had
one subject in each who died prior to the onset of any neurologic-
al symptoms yet must have been obligate carriers—one died
at age 34 and the other at age 72. In 11 (26%) kindreds, the
most recent generation of affected subjects had an age of onset
410 years younger than the previous generation (Supplementary
Fig. 1).
Table 1 Frequency of the non-coding GGGGCC hexanucleotide repeat expansion in C9ORF72 among the three Mayo Clinic
cohorts
Characteristic/feature Mayo Clinic Rochester
FTD cohort
Mayo Clinic Florida
FTD cohort
Mayo Clinic Florida
ALS cohort
Total cases screened 178 197 229
Expansion detected 20
a (11.2%) 7 (3.6%) 16 (7.0%)
Family history of dementia, parkinsonism, or ALS
b 94 80 34 (39)
Expansion detected 18 (19.1%) 5 (6.3%) 8 (23.5%) [13 (38.2%)]
Sporadic cases
b 84 117 195 [190]
Expansion detected 2 (2.4%) 2 (1.7%) 8 (4.1%) [3 (1.6%)]
c
a Includes the Vancouver–San Francisco–Mayo Clinic Family 20 proband in the Mayo Clinic Rochester FTD cohort.
b Family history (see text for details). Of note, the eight cases from the Mayo Clinic Florida ALS cohort had no ﬁrst- or second-degree relatives with ALS, which is the
published criterion for considering ‘familial ALS’. Five of them had one or more ﬁrst- or second-degree relatives with dementia or parkinsonism. Therefore, using strict
criteria for sporadic disease being the absence of any ﬁrst- or second-degree relatives with dementia, parkinsonism or ALS, the values in brackets reﬂect these strict
criteria such that 2 + 2 + 3 = 7 (16%) out of 43 probands were sporadic.
c One of the three is adopted with no conﬁrmed family history of dementia or ALS.
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The demographic and clinical ﬁndings of pertinent members of the
43 kindreds are presented in Supplementary Table 1. A summary
of the key demographic ﬁndings is presented in Table 4. Details
regarding our index kindred have been previously reported (Boxer
et al., 2011).
Demographic features
All subjects were Caucasian. There was a very slight male predi-
lection considering all cases and only clinically deﬁnite cases, and
there was a trend towards subjects with behavioural variant FTD
being more represented by males (63%) and those with
ALS  FTD being more represented by females (60%). Among
the 63 examined subjects from the 43 families (33 male, 52%)
with clinically deﬁnite behavioural variant FTD and/or
ALS  parkinsonism, age at onset ranged from 33 to 72 years
(median 52 years). Age at death ranged from 35 to 75 years
(median 60 years), and survival ranged from 1 to 17 years
(median 5 years). Four of the clinically deﬁnite cases survived 10
years or more, all of whom had the behavioural variant FTD
phenotype. Among the 63 with clinically deﬁnite disease, six
(10%) had onset of symptoms prior to age 40, 19 (30%) had
onset of symptoms after age 60, and three (5%) had onset of
symptoms after age 70; the maximal age of onset was 72 years.
Also, one man with an Alzheimer’s disease-like phenotype who
was not examined by any of the authors had a dementia onset of
74 years and death age of 84 years. He underwent neuropatho-
logical examination and FTLD-MND was identiﬁed. Therefore, the
age of onset and duration of disease appear quite variable among
those with c9FTD/ALS.
Clinical phenotypes
Similar data are shown in Table 4 for those with the dominant
clinical phenotype (henceforth labelled as ‘primary diagnosis’) of
behavioural variant FTD, ALS and combined FTD/ALS, and
Table 2 Frequency of the non-coding GGGGCC hexanucleotide repeat expansion in C9ORF72, and mutations in MAPT,
PGRN and other genes among the syndromes of behavioural variant FTD, FTD/ALS and ALS
Characteristic/feature Behavioural variant FTD FTD/ALS ALS
Total cases screened, n 210 51 195
C9ORF72 expansion detected, n (%) 19 (9.0) 11 (21.6) 13 (6.7)
MAPT mutation detected, n (%) 16 (7.6) 0 0
PGRN mutation detected, n (%) 10 (4.8) 0 0
Family history of dementia, parkinsonism or ALS 102 21 25
C9ORF72 expansion detected, n (%) 15 (14.7) 10 (47.6) 6 (24.0)
MAPT mutation detected, n (%) 13 (12.7) 0 0
PGRN mutation detected, n (%) 7 (6.8) 0 0
Mutation in other gene detected
a, n (%) 0 0 6 (24.0)
No mutation in C9ORF72, MAPT,o rPGRN, or other genes detected, n (%) 67 (65.7) 11 (52.4) 13 (52.0)
Sporadic cases
b 108 30 170
C9ORF72 expansion detected, n (%) 4 (3.7) 1 (3.3) 7 (4.1) [2 (1.2)]
a
MAPT mutation detected, n (%) 3 (2.8) 0 0
PGRN mutation detected, n (%) 3 (2.8) 0 0
a Mutations in other genes include TARDBP (n =1 ) ,FUS (n =1 )a n dSOD1 (n =4 ) .
b See text for details on determining familial versus sporadic. Of note, while seven of the cases with ALS had no ﬁrst- or second-degree relatives with ALS, which is the
published criterion for considering ‘familial ALS’, ﬁve of them had one or more ﬁrst- or second-degree relatives with dementia or parkinsonism. Therefore, using strict criteria
for sporadic disease being the absence of any ﬁrst- or second-degree relatives with dementia, parkinsonism or ALS, the values in brackets reﬂect these strict criteria such that
7 – 5 = 2 (1.2%) out of 170 cases were sporadic.
FUS = gene encoding fused in sarcoma; MAPT = gene encoding microtubule associated protein tau; PGRN = gene encoding progranulin; SOD1 = gene encoding super-
oxide dismutase-1; TARDBP = gene encoding TARD binding protein.
Table 3 Summary of inheritance observations among affected individuals in 43 kindreds with
probands harbouring the non-coding GGGGCC hexanucleotide repeat expansion in C9ORF72
Inheritance observation n (%)
Kindreds with apparent autosomal dominant pattern of inheritance 36 (84)
Only dementia or behavioural variant FTD present in same kindred 12 (33)
Only ALS phenotype present in same kindred 3 (8)
FTD and ALS phenotype present in same kindred 21 (58)
Apparent sporadic cases with no known family history of neurodegenerative disease 7 (16)
Apparent kindreds with incomplete penetrance 2 (5)
Apparent younger age of onset (410 years) from one generation to the next 11 (26)
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onset regardless of the major clinical phenotype was 52 years, and
the survival tended to be shorter for those with ALS (median 3
years) compared with those without (median 6 years). Among the
12 subjects with combined FTD/ALS, the behavioural variant FTD
syndrome preceded the ALS features in seven by a median of
2 years (range 1–4 years), the ALS features preceded the behav-
ioural variant FTD syndrome in two by a median of 2.5 years
(range 2–3 years), and the behavioural variant FTD and ALS
evolved concurrently in three.
Absence of primary progressive aphasia phenotype
Although all subjects in the Mayo Clinic Rochester and Mayo
Clinic Florida clinical cohorts with the progressive non-ﬂuent apha-
sia (now termed non-ﬂuent/agrammatic subtype of primary pro-
gressive aphasia, n = 76) and semantic dementia (now termed
semantic subtype of primary progressive aphasia, n = 65) pheno-
types were screened for the hexanucleotide repeat expansion,
none with a primary progressive aphasia diagnosis (0 out of
141) were found to have the expansion (Tables 2 and 4).
Parkinsonism
Among the clinically examined subjects, 22 (35%) showed evi-
dence of parkinsonism. In 14 (64%) of those with parkinsonism,
the extrapyramidal features evolved within the ﬁrst 2 years of the
onset of the FTD  ALS features. All who had parkinsonism
had the dominant clinical phenotype of behavioural variant FTD
(15 out of 30 or 50% of subjects with behavioural variant FTD) or
FTD/ALS (5 out of 12 or 42% of subjects with FTD/ALS), but not
ALS (0 out of 18). Parkinsonism was characterized as a relatively
symmetric akinetic-rigid syndrome, and the few in whom tremor
was present, it was prominent with posture and action but not at
rest. None in whom levodopa was administered beneﬁted from
this treatment, and none were diagnosed with Parkinson’s disease.
Amyotrophic lateral sclerosis features
Among the clinically examined subjects, 28 (44%) subjects had
clinical ﬁndings allowing El Escorial classiﬁcation of ALS, and 27
(43%) underwent electromyography. The frequency of ALS diag-
noses using the El Escorial criteria designations considering all
examined cases were as follows: deﬁnite (n = 10, 16%), probable
(n = 8, 13%), possible (n = 4, 6%), probable laboratory-supported
(n = 4, 6%), suspected (n = 1, 2%), and not applicable (n = 36,
57%). The site of onset was bulbar in seven, upper spinal cord in
13, and lower spinal cord in eight. A few rare phenotypes were
present, with one subject having monomelic amyotrophy (one
upper extremity affected), one had progressive muscular atrophy,
and one had a combination of pseudobulbar affect, mixed ﬂaccid/
spastic dysarthria, profound spasticity in the limbs most consistent
with a primary lateral sclerosis phenotype plus lower motor neuron
ﬁndings in the bulbar musculature.
Evidence of upper motor neuron and/or lower motor neuron
dysfunction was also found in many cases with dementia with
or without parkinsonism, but did not involve multiple neuraxis
levels to warrant a coexisting diagnosis of suspected, possible,
probable or deﬁnite ALS by El Escorial criteria. Twelve (40%) of
the 30 subjects with behavioural variant FTD or dementia had
clinical evidence of upper motor neuron dysfunction, and one
(3%) had evidence of lower motor neuron dysfunction.
Other clinical features
Also among all clinically examined subjects, the following clinical
ﬁndings were identiﬁed: memory dysfunction (n = 23), aphasia
(n = 20), frontal release signs (n = 8) and pseudobulbar affect
(n = 4). The degree of memory dysfunction varied from mild to
marked, and when present, this was often evident early in the
disease course. Aphasia tended to be a late feature, with some
becoming mute late in the course.
Table 4 Summary of clinical phenotypes and demographic data among affected individuals in 43 kindreds with probands
harbouring the non-coding GGGGCC hexanucleotide repeat expansion in the gene C9ORF72
Dominant clinical phenotype or feature Total Male,
n (%)
Age at
onset
Median
(range)
(in years)
Age at
death
Median
(range)
(in years)
Survival
Median
(range)
(in years)
Sx540,
n (%)
Sx460,
n (%)
Sx470,
n (%)
Dementia, parkinsonism or ALS 103 56 (54) 56 (33–85) 66 (34–90) 5 (1–26) 7 (7) 47 (46) 20 (19)
Clinically deﬁnite bvFTD and/or
ALS  parkinsonism
63 33 (52) 52 (33–72) 59 (35–75) 5 (1–17) 6 (10) 19 (30) 3 (5)
Primary diagnosis of bvFTD  parkinsonism 30 19 (63) 52 (33–69) 61 (35–75) 6 (1–17) 2 (7) 9 (30) 0
Primary diagnosis of ALS 18 7 (39) 53 (35–72) 55 (37–73) 4 (1–6) 1 (4) 4 (22) 1 (4)
Primary diagnosis of FTD/ALS  parkinsonism 12 5 (42) 53 (38–71) 57 (39–75) 3 (1–9) 2 (14) 3 (21) 1 (7)
Primary diagnosis of PPA
a 0
Presence of bvFTD features among subjects
with a primary ALS diagnosis
b (n = 18)
3 (17)
Presence of ALS features among subjects with
a primary bvFTD diagnosis
b (n = 30)
12 (40)
Presence of parkinsonism
b (n = 63) 22 (35)
a Includes 76 cases with the non-ﬂuent/agrammatic and 65 with the semantic subtypes of PPA.
b Only includes examined subjects. All subjects with parkinsonism had behavioural variant FTD or FTD/ALS, but not ALS, as the dominant clinical phenotype.
bvFTD = behavioural variant frontotemporal dementia; PPA = primary progressive aphasia.
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psychiatric features was available in 20 subjects (16 with be-
havioural variant FTD, three with FTD/ALS and one with ALS).
The frequency of delusions was 45%, frequency of hallucinations
was 50% and changes in appetite/eating behaviour was 100%.
Two of the three cases with FTD/ALS had all three of these
features.
Neuropsychological ﬁndings
Screening exams
Twelve subjects (mean age 58.1  9.08 years) completed a
Mini-Mental State Examination and obtained a mean score of
20.5  6.75 (range 7–28). Seven of these 12 (58.3%) subjects
obtained a Mini-Mental State Examination score 524/30.
Twenty-three subjects (mean age 57.8  7.66 years) completed
a Dementia Rating Scale-2 and obtained a mean score of
108.5  24.40 (range 56–139). Dementia Rating Scale-2 scores
were in the impaired range for 18 of 23 (78.3%) subjects.
Three additional subjects received the Amyotrophic Lateral
Sclerosis-Cognitive Behavioural Screen: one individual obtained
an impaired cognitive score of 13/20, another individual was
unable to complete the test due to the severity of cognitive im-
pairment, while the third individual obtained a cognitively normal
score of 17/20.
Neuropsychological battery
As shown in Fig. 1, subjects demonstrated predominant impair-
ment across timed tasks, with a high percentage showing speciﬁc
deﬁcits on measures of complex attention/executive functioning
and word ﬂuency. There were no obvious differences in the
neuropsychological proﬁle of impairment between the behaviour-
al variant FTD, FTD/ALS and ALS phenotypes. Fewer subjects
were impaired on tests of basic attention, memory and visual
naming. No subject was impaired on a test of single word read-
ing, suggesting relative sparing of this ability and highlighting
that test’s utility as an index of estimated premorbid cognitive
function in FTD/ALS. The discrepancy in impairment between
two tests involving visuospatial functioning (Block Design and
Judgement of Line Orientation) is worth noting. Block Design
is a timed task that requires motor manipulation of blocks to
match target designs and relies on processing speed, visuospatial
skills and an executive problem-solving component. In contrast,
Judgement of Line Orientation is a non-timed task that requires
visual discrimination of angular relationships. Eleven of the 13
subjects who completed Block Design obtained an impaired
score (84.6%), compared with 1 of 11 (9.1%) subjects who
completed the Judgement of Line Orientation task. Of the ﬁve
subjects who completed both tasks, all had lower scores on
Block Design and their mean score was 1 standard deviation
below their mean score on Judgement of Line Orientation. These
results, although from a limited number of subjects, suggest that
0
10
20
30
40
50
60
70
80
90
D
.
S
p
a
n
L
.
M
e
m
A
V
L
T
 
/
 
C
V
L
T
-
I
I
V
.
R
e
p
B
N
T
C
O
W
A
T
C
a
t
.
 
F
l
u
e
n
c
y
T
M
T
-
B
 
S
t
r
o
o
p
 
C
/
W
B
.
 
D
e
s
i
g
n
J
L
O
W
R
A
T
-
3
 
*
P
e
r
c
e
n
t
 
o
f
 
s
u
b
j
e
c
t
s
 
i
m
p
a
i
r
e
d
Figure 1 Per cent of subjects with impaired neuropsychological test scores. Cognitive impairment deﬁned as test scores less than 1.5
SDs from respective normative sample. AVLT = Auditory Verbal Learning Test; B.Design = Block Design; BNT = Boston Naming Test;
Cat. Fluency = Category Fluency; COWAT = Controlled Oral Word Association Test; CVLT-II = California Verbal Learning Test-II;
D.Span = Digit Span; JLO = Judgement of Line Orientation; L. Mem = Logical Memory; Stroop C/W = Stroop colour-word interference
trial; TMT-B = Trail Making Test part B; V. Rep = Visual Reproduction; WRAT-3 = Reading subtest from the Wide Range Achievement
Test-3. Asterisk represents no subject impaired in WRAT-3 Reading test.
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due to slowed processing speed and executive dysfunction, not
visuospatial deﬁcits.
Neuroimaging ﬁndings
Magnetic resonance imaging
MRI was available for review in 18 patients (14 with behavioural
variant FTD, three with FTD/ALS and one with ALS), and repre-
sentative images highlighting the relatively consistent pattern of
symmetric bilateral frontal  temporal cortical atrophy are
presented in Fig. 2. Signiﬁcant atrophy was determined in individ-
ual subject MRI scans using a threshold of Z-score less than 2.5.
Atrophy was identiﬁed in 15 patients, with frontotemporal pre-
dominance in 12. One patient with behavioural variant FTD, one
with FTD/ALS and one with ALS had no detectable atrophy.
Parietal cortical atrophy was present in ﬁve patients and insular
atrophy was found in eight patients. Subcortical white matter
signal changes were absent in all cases. Longitudinal MRI scans
spanning 52 years were available in eight patients, which all
showed progression of atrophy speciﬁcally in the frontal lobes
and ventricular enlargement.
Figure 2 Atrophy patterns in individual subjects. MRI scans of individual subjects overlaid with regions of severe atrophy in yellow using
MRI STAND-maps (Z-score less than 2.5 relative to normals was used as a threshold). The brightness of the overlaid colour indicates the
degree of atrophy. Numbers represent age of each subject in years. Kind = kindred; P = proband; R = relative.
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SPECT scans were available for analysis in four subjects (Fig. 3).
The ﬁndings indicate statistically signiﬁcant anterior and middle
cingulate gyri hypoperfusion compared with controls (P = 0.037)
(Supplementary Fig. 2). One subject (Kindred 16, Case IV.2) who
had normal ﬁndings on his initial MRI (Fig. 1) also underwent both
SPECT and PET imaging, and each showed anterior cingulate
changes. However, the frontal cortical changes were more prom-
inent on the PET when the subject was also 2 years older.
Five subjects underwent FDG-PET. In four of ﬁve FDG-PET scans
(Fig. 4), anterior cingulate Z-scores were signiﬁcant (average right
2.2; average left 1.9) and showed consistent hypometabolism in
these subjects. Posterior cingulate metabolism was normal in these
subjects (average right 0.98; average left 0.98). Frontal cortical
hypometabolism in these four subjects ranged from mild to
severe. One of the ﬁve subjects had a parietal/precuneus pattern
of hypometabolism with sparing of frontal cortical regions. These
SPECT and PET ﬁndings have regional abnormalities that show
localization similarities with the salience network (Supplementary
Fig. 3).
Neuropathological ﬁndings
Neuropathological data were available for 14 affected individuals
(summarized in Supplementary Table 2); data on two of these
cases were reported previously (Murray et al., 2011). All had
TDP-43 pathology associated with frontal and variable parietal
or temporal cortical atrophy and microscopic evidence of neuro-
degeneration (Fig. 5 and Supplementary Fig. 4); nine had path-
ology consistent with MND (FTLD-MND). Alzheimer’s type
pathology was minimal and none met research criteria for
Alzheimer’s disease; two patients with moderate CERAD neuritic
plaques and one subject with Braak neuroﬁbrillary tangle stages III
and IV were all 70 years of age or older. Substantia nigra degen-
eration was common and moderate-to-severe in seven of nine
patients with FTLD-MND, but zero of ﬁve FTLD-TDP. None of
the cases had Lewy bodies with -synuclein immunohistochemis-
try. Of the seven cases with the most severe substantia nigra
degeneration, three had parkinsonism that ranged from
mild-to-severe. Hippocampal sclerosis was relatively uncommon
and severe in only 4 of the 14 cases. Of the cases with FTLD-
MND, seven showed both upper and lower motor neuron path-
ology consistent with ALS, the remaining two (Kindred 10, Case
III.2; Kindred 12, Case IV.1) showed only involvement of lower
motor neuron with no corticospinal tract degeneration and were
consistent with progressive muscular atrophy. Two of the cases
with FTLD-MND were considered to have preclinical MND since
they had no documented clinical ﬁndings of MND. Bunina bodies
were found in all cases with FTLD-MND, except one case who
showed very subtle lower motor neuron neuronal loss and sparse
TDP-43-positive pathology.
The cases were classiﬁed as Mackenzie type 1 (harmonized type
A, n = 10), Mackenzie type 3 (harmonized type B, n = 4). Half of
the cases with FTLD-MND were type A and half were type B. Two
cases with type A FTLD-TDP had no evidence of motor neuron
loss or corticospinal tract degeneration, but isolated motor neurons
in spinal cord with either a Lewy body-like hyaline inclusion or a
Figure 3 Individual subject relative SPECT intensity maps.
SPECT maps shown for a 54-year-old healthy control subject
(A), 51-year-old with behavioural variant FTD (B), 51-year-old
with behavioural variant FTD (C), 56-year-old with FTDP/ALS
(D), and 63-year-old with behavioural variant FTD (E). The
relative SPECT intensity for each subject’s normalized SPECT
scans is overlaid on a template brain for anatomical reference.
The healthy control subject is displayed at the top (blue box),
and images for subjects B to E are arranged in increasing order
of severity of anterior cingulate reduction in SPECT intensity.
Colour bar encodes SPECT intensity relative to pontine region
of interest.
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in the group with MND the overwhelming majority of cases would
be type A. Regardless, type A in our series is more common than
type B in c9FTD/ALS, in contrast to the conclusions of the authors
in the harmonization group (Mackenzie et al., 2011).
Cerebellar granular cell ubiquitin-immunoreactive neuronal in-
clusions were detected in all but three patients (all FTLD-MND,
one type A and two type B). They tended to be more numerous in
type A than type B and in FTLD-TDP rather than FTLD-MND. In
almost all cases, ubiquitin tended to label more neuronal inclusions
in the hippocampal dentate fascia and dystrophic neurites in the
molecular layer of the dentate fascia than TDP-43 (Fig. 5), similar
to ﬁndings recently reported by Al-Sarraj and colleagues (2011).
Moreover, the frequency of ubiquitin-positive inclusions compared
with TDP-43 could affect the interpretation of TDP-43 type.
A summary of the salient features and ﬁndings associated with
the C9ORF72 mutation is shown in Table 5.
Discussion
The core features of chromosome 9
FTD/ALS
There was a relatively characteristic spectrum of core ﬁndings
among individuals with FTD and/or ALS associated with the hex-
anucleotide repeat expansion in C9ORF72, which we suggest
should be termed c9FTD/ALS. The phenotype was typically
behavioural variant FTD, ALS or a combination of both. Features
of parkinsonism were found in nearly one half of patients with
behavioural variant FTD or FTD-ALS but were not seen in patients
with ALS in these cohorts. No patient had a primary dementia
phenotype of primary progressive aphasia. The age of onset was
in the 33–75 year range, and survival ranged widely, with most
succumbing to the disease within 7 years from onset. Those with
Figure 4 Fluorodeoxyglucose-PET Z-score 3D-SSP images. PET images shown for a 68-year-old with behavioural variant FTD (A),
69-year-old with behavioural variant FTD (B), 64-year-old with behavioural variant FTD (C), 53-year-old with behavioural variant FTD
(D), and 57-year-old with behavioural variant FTD (E). The images from left to right are right lateral, left lateral, right medial, and left
medial Z-score projection maps. The upper two rows show mild frontal cortical and cingulate hypometabolism while the lower two show
moderate to severe dorsolateral frontal, anterior temporal cortical and cingulate hypometabolism. The middle subject images show a
parietal/precuneus pattern of hypometabolism. Subject D in this ﬁgure is the same person as Subject B in Fig. 3.
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tended to have a shorter disease course. Most had one or more
relatives with dementia and/or ALS. The neuroimaging ﬁndings of
symmetric bilateral frontal  parietal and/or temporal cortical
changes were relatively consistent. All patients with autopsies
and neuropathological examinations had TDP-43 pathology con-
sistent with either type A or Type B, as well as frequent motor
neuron pathology, frequent substantia nigra degeneration and
ubiquitin-positive, TDP-43-negative cerebellar and hippocampal
neuronal inclusions.
Demographic considerations
Among all subjects with dementia and/or ALS, and among only
those who were examined by one of the co-authors, there was a
slight male predominance (52–54%). Considering these three co-
horts together, males with the primary diagnosis of behavioural
variant FTD were over-represented (63%), and females with
ALS  FTD were slightly over-represented (18/30 or 60%), par-
ticularly in the ALS phenotype (61%), but whether these slight
male–female differences reﬂect a sampling bias or have biological
relevance in terms of sex factors impacting the topography of
degeneration and hence the clinical phenotype will require further
study.
Genetic/inheritance considerations
Among the three cohorts of subjects, the frequency of the muta-
tion was highest in the Mayo Clinic Rochester FTD cohort (11.2%
of all FTD  ALS cases) and lowest in the Mayo Clinic Florida FTD
cohort (3.6%), which likely reﬂects the strong focus of recruiting
familial FTD kindreds in the Mayo Clinic Rochester centre and
likely higher frequency of northern European ancestry in the
Midwest (which is where most Mayo Clinic Rochester participants
reside). Among those with a positive family history, the frequency
of the expansion was highest in the Mayo Clinic Florida ALS
cohort (at least 23%), but also reasonably high in the Mayo
Clinic Rochester FTD cohort (19.1%). There are likely two factors
that explain this. The newly identiﬁed C9ORF72 mutation explains
a high proportion of familial ALS based on the available data
Figure 5 Microscopic ﬁndings of c9FTD/ALS. Ubiquitin immunohistochemistry (A) compared with phospho-TDP-43 immunohisto-
chemistry (B) in adjacent sections of dentate fascia of hippocampus (Kindred 14, Case 1.III.1). Note considerably more neuronal inclusions
and neurites with ubiquitin. Ubiquitin-positive cerebellar inclusions in same case at lower magniﬁcation (C) and higher magniﬁcation (D).
Frontal cortex phospho-TDP-43 immunohistochemistry: type A in Patient III.1 from Kindred 5 shows short neurites, neuronal inclusions
and intranuclear inclusions (inset); and type B in Patient IV.1 from Kindred 12 shows mostly neuronal inclusions, including so-called
‘pre-inclusions’. Scale bar = 30mm for A–C, E and F and 6mm for D and E inset.
776 | Brain 2012: 135; 765–783 B. F. Boeve et al.(DeJesus-Hernandez et al., 2011; Renton et al., 2011).
Furthermore, other data suggest that a common founder from
Scandinavia might underlie the disease (Mok et al., 2012). More
work is needed to determine if the mutation stems from a
common founder, represents a ‘weak point’ in the genome
which allows an increased frequency of expansions to randomly
occur, or a combination of these and other factors.
As shown in Table 2, the frequency of the C9ORF72 mutation is
highest in the FTD/ALS phenotype compared with the behavioural
variant FTD and ALS phenotypes regardless of whether they are
considered among all cases or familial cases only. Furthermore, no
mutations in MAPT or PGRN were detected in the cases with
sporadic or familial FTD/ALS and ALS. Also, at least in this
Mayo Clinic series, the frequency of familial behavioural variant
FTD being explained by the C9ORF72 mutation is higher than that
explained by MAPT and PGRN despite the strong interest in
recruiting familial FTD families over the past 20 years and contri-
butions to the original identiﬁcation of mutations in MAPT and
PGRN causing familial FTD. These data therefore indicate that a
sizable proportion of cases with familial FTD and/or ALS is
explained by the C9ORF72 mutation. Importantly, however, an
even greater proportion is not explained by mutations in these
three or other known genes (450% for each phenotype), indicat-
ing that other yet-to-be-identiﬁed genes are associated with FTD
and/or ALS.
More than 80% of our probands were familial, of which
more than half had both the behavioural variant FTD and ALS
phenotypes represented in the kindreds, a third had only dementia
or behavioural variant FTD, and the remaining minority had only
ALS represented in the families. Therefore, the repeat expansion
should be considered in any kindred with familial FTD and/or
ALS. The other 16% of our probands did not meet predeﬁned
criteria for a positive family history and hence were considered
sporadic.
The observation that the GGGGCC hexanucleotide repeat ex-
pansion in C9ORF72 may be associated with FTD, FTD/ALS and
Table 5 Salient features of c9FTD/ALS due to the GGGGCC hexapeptide repeat expansion in C9ORF72
Demographic
Males and females appear approximately equally affected
Age of onset is between 33 and 72 years, with most presenting in the 40–70 year age range
Survival is variable but typically in the 3–10 year range
Survival is shorter when the ALS phenotype is present
Inheritance
Inheritance is autosomal dominant
Some examples of incomplete penetrance do exist
Apparently sporadic cases do exist
Some kindreds appear to exhibit an anticipation-like phenomenon
Clinical
The characteristic phenotypes include behavioural variant FTD, ALS or FTD/ALS
Many with the behavioural variant FTD predominant phenotype have evidence of upper and/or lower motor neuron involvement
Some with the ALS predominant phenotype have features of behavioural variant FTD
The primary progressive aphasia and corticobasal syndrome phenotypes appear to be uncommonly associated with this mutation
Psychosis and appetite/eating changes are common
Parkinsonism is common and typically of the akinetic-rigid type without tremor
Neuropsychological
Most cases have impairment on measures of complex attention/executive functioning and verbal ﬂuency
Performance in other domains is more variable, with most having more minimal or no impairment on measures of episodic memory,
confrontation naming and visuospatial functioning
Neuroimaging
On MRI, most cases have symmetric bilateral frontal  temporal cortical atrophy; remarkably minimal atrophy can be apparent early
in the course
On SPECT or PET, most cases have symmetric bilateral frontal  temporal cortical abnormalities, with the anteromedial cingulate region
being most consistently affected
Neuropathology
All cases have TDP-43 positive pathology, with some having features most consistent with harmonized type A FTLD-TDP pathology
and others having features most consistent with type B pathology.
Ubiquitin-positive neuronal inclusions are very common in the cerebellar granule cells.
Motor neuron degeneration and substantia nigra degeneration are common.
Hippocampal sclerosis is uncommon or less severe in cases with motor neuron disease
SPECT = single photon emission computed tomography.
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recently proposed criteria for the diagnosis of familial ALS (Byrne
et al., 2011). In the Mayo Clinic Florida ALS cohort we classiﬁed
eight patients who carried the C9ORF72 repeat mutation and had
no known family history of ALS in a ﬁrst- or second-degree rela-
tive, as sporadic ALS. However, available information suggests
that ﬁve of these eight patients might be reasonably classiﬁed as
having a familial disorder given a family history of dementia in a
ﬁrst-degree relative in four and in a second-degree relative in one
patient. The latter classiﬁcation is in keeping with criteria we
applied in designating patients with FTD and FTD/ALS as familial
or sporadic. This leaves a small number of patients with FTD or
ALS in whom family history suggests sporadic disease, but evalu-
ation of parental DNA will be important in future investigation to
determine whether these pedigrees represent non-penetrance or
spontaneous expansion of the GGGGCC hexanucleotide repeat
from a non-pathogenic parental form. Adoption of stringent cri-
teria for the diagnosis of familial ALS along the lines of those
recently proposed by Byrne et al. (2011) seems especially import-
ant in giving increasing recognition that expanded phenotypes
such as extrapyramidal disease may be associated with genes
linked to FTD and ALS.
Whether the sporadic cases represent incomplete penetrance or
de novo mutations is being investigated. Two subjects appeared to
be obligate carriers but died while neurologically asymptomatic—
one at age 34 from an accident, and another at age 72 from a
myocardial infarction. The younger subject might have exhibited
features had he survived decades more, and the 72-year old may
have done likewise if he had survived a few more years. However,
considering that 72 was the maximal age of onset of any clinically
examined subject in this series, and the subject with the
Alzheimer’s disease phenotype whose onset was at the age of
74 and autopsy revealed FTLD-TDP-43 pathology (the repeat ex-
pansion has not been conﬁrmed in this case but is presumed), this
asymptomatic case who died at age 72 suggests that incomplete
penetrance might occur even among aged individuals.
A curious observation is the apparent earlier age of onset (410
years) in the youngest generation compared with the previous
generation in 11 (26% of all probands) of our families with
c9FTD/ALS (Supplementary Fig. 1). Considering that the mechan-
ism of this genetic defect involves a hexanucleotide repeat expan-
sion, and the concept of anticipation (i.e. an earlier age of onset in
successive generations occurs with increasing repeat length) is well
established in many of the nucleotide repeat disorders (Lindblad
and Schalling, 1999), it is tempting to hypothesize that a similar
mechanism may be at play in these families. However, this will be
challenging to study. First, the repeat expansion is unstable
and variable across cells, and variability in single subjects has
already been seen (DeJesus-Hernandez et al., 2011).
Furthermore, the current methodology for quantifying repeat
length is imperfect, particularly when several hundreds of repeats
are present. Investigating this issue further is clearly worthy to
support or refute an anticipation mechanism associated with this
hexanucleotide repeat. Repeat length may also impact the topog-
raphy of neurodegeneration and hence the clinical phenotype
expressed.
Clinical considerations
As noted above, the core phenotypes associated with this repeat
expansion were behavioural variant FTD, ALS or combined FTD/
ALS, with one-third of total cases and nearly half with behavioural
variant FTD or FTD/ALS also having some degree of parkinsonism,
which was typically an akinetic-rigid syndrome without rest
tremor. When parkinsonism was present, it tended to evolve
over the initial 2 years of the disease course. When both behav-
ioural variant FTD and ALS occurred in the same individual, the
features almost always evolved within 2 years. Even among sub-
jects with the primary behavioural variant FTD syndrome, almost
40% in this series had some degree of upper and/or lower motor
neuron dysfunction but not of sufﬁcient breadth to warrant the
FTD/ALS diagnosis. A comprehensive neurological examination in
any patient with dementia will permit identiﬁcation of these clin-
ical ﬁndings. Almost 20% of the subjects with a primary diagnosis
of ALS had some degree of behavioural variant FTD features but
either did not fully meet criteria for the FTD/ALS diagnosis or
could not be formally evaluated owing to motor impairment.
Features of behavioural variant FTD may be subtle and not char-
acteristic of fully developed dementia in ALS resulting in potential
misattribution of signs of cognitive dysfunction to situational fac-
tors or depression. Weakness and fatigue may limit the practical
assessment of FTD in subjects with ALS, and eliciting the historical
and clinical features of behavioural variant FTD may not be rou-
tinely performed in clinics focused on standard elements of ALS
patient care. Thus, the 20% frequency of behavioural variant FTD
features in this cohort of subjects with ALS may be an underesti-
mate. Yet the overlapping features of behavioural variant FTD and
ALS in many subjects with the repeat expansion in C9ORF72
underscores several key points: (i) this genetic alteration can
impact cognition, behaviour and motor functioning via degener-
ation in cerebral and/or spinal cord neurons; (ii) clinicians will
often identify ALS features in subjects with behavioural variant
FTD and behavioural variant FTD features in subjects with ALS if
detailed questioning, clinical examinations and electromyograms
are performed (Lomen-Hoerth et al., 2002, 2004); and (iii) assess-
ments over time permit the identiﬁcation of more widespread
ﬁndings as the disease process evolves.
Neuropsychiatric morbidity was frequent in the subjects in
whom this information was collected. The caregivers of subjects
endorsed the presence of changes in appetite and eating behav-
iour in all who were queried, and almost half endorsed the pres-
ence of delusions or hallucinations. These ﬁndings are consistent
with other recent publications on the neuropsychiatric features in
FTD/ALS and/or those with TDP-43 positive pathology (Lillo
et al., 2010; Burrell et al., 2011; Piguet et al., 2011).
Among the clinically examined subjects, most with ALS features
fulﬁlled El Escorial criteria for deﬁnite, probable or possible ALS,
and the site of onset was approximately equal across the bulbar,
upper and lower spinal cord segments. The rare variants included
atypical primary lateral sclerosis (no DNA available), monomelic
ALS (mutation identiﬁed), and progressive muscular atrophy (mu-
tation identiﬁed). Although most had ALS-like ﬁndings, neuro-
pathological studies also showed patients with motor neuron
degeneration consistent with progressive muscular atrophy.
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variant, particularly with a positive family history of FTD and/or
ALS.
Importantly, none of our cases with FTD/ALS with early and
profound aphasia, nor any of our non-ﬂuent/agrammatic and se-
mantic subtypes of primary progressive aphasia, were found to
have a hexanucleotide repeat expansion. This observation not
only has diagnostic relevance, but also suggests the repeat expan-
sion on C9ORF72 affects cerebral networks in a more bilateral,
patchy or diffuse manner as opposed to a focal/asymmetric
manner which is what the primary progressive aphasia syndromes
reﬂect. If this repeat expansion is also found to be rare or
non-existent in other focal/asymmetric cortical degeneration syn-
dromes such as the corticobasal syndrome, associative agnosia/
prosopagnosia, posterior cortical atrophy, etc., this concept of clin-
ical features reﬂecting more symmetric, patchy or relatively diffuse
cerebral neurodegeneration will need to be explained based on
the mechanism of how the repeat expansion causes cerebral
dysfunction.
Neuropsychological considerations
Consistent with the phenotypic presentation of FTD/ALS, the
predominant cognitive proﬁle in subjects with the C9ORF72
hexanucleotide repeat expansion is associated with slowed pro-
cessing speed, complex attention/executive dysfunction and im-
pairment in rapid word retrieval. This pattern of dysfunction
implicates frontal lobe structures and subcortical pathways invol-
ving dorsolateral prefrontal cortex and anterior cingulate. In con-
trast, naming, episodic memory, word reading and gross
visuoperceptual/spatial skills are relatively spared, suggesting infre-
quent or minimal involvement of temporal and parietal lobe
structures.
Approximately one-third of our subjects did not demonstrate
impairment on cognitive screening measures. This ﬁnding may re-
ﬂect the known poor sensitivity of screening measures to execu-
tive dysfunction or the presence of cases with behavioural variant
FTD that have yet to develop cognitive deﬁcits. It also bears
noting that neuropsychological tests in common practice may
not capture the entire spectrum of cognitive impairment possible
in behavioural variant FTD or FTD/ALS (Torralva et al., 2009).
Thus, the need for broad-based and more sensitive measures of
cognitive assessment will become paramount when evaluating
subjects in the presymptomatic and early symptomatic stages of
the disease.
Neuroimaging considerations
The syndrome of behavioural variant FTD is typically associated
with mild to marked frontal and/or temporal lobe abnormalities,
particularly in the non-dominant cerebral hemisphere (usually
right), on structural and functional neuroimaging studies (Miller
et al., 1991; Rosen et al., 2002; Foster, 2003; Whitwell et al.,
2004, 2005, 2009; Whitwell and Jack, 2007; Rohrer, 2011). On
MRI, the degree of cerebral cortical atrophy in patients with
C9ORF72 mutation tended to be rather mild, and was most
apparent in the dorsolateral prefrontal and insular cortex.
The temporal lobes were normal to only mildly affected. Some
degree of parietal cortical atrophy was evident in some cases.
And, the pattern of atrophy was never in a strikingly focal or
asymmetric manner in any of our cases. Signal changes on
T2-weighted and ﬂuid attenuation inversion recovery images in
the cortex or subcortical white matter were also minimal or
non-existent.
The ﬁndings on SPECT and PET were similar to those on MRI,
with the dorsolateral prefrontal cortex, and anterior  medial cin-
gulate cortex involved. This topography of atrophy, hypoperfusion
and hypometabolism correlates well with other features such as
the prominent apathy and inertia as part of the behavioural variant
FTD phenotype. The neuroimaging ﬁndings are also correlated
with poor performance on neuropsychological measures that
assess psychomotor speed, word ﬂuency and sustained attention.
Similar to the MRI ﬁndings in some subjects, the degree of hypo-
perfusion on SPECT or hypometabolism on PET was quite mild in
some despite the presence of an obvious behavioural variant FTD
syndrome. Also, a few cases had atrophy on MRI or hypometa-
bolism on PET that was apparent in the biparietal/precuneus
regions.
Therefore, abnormalities on neuroimaging studies that max-
imally involve the dorsolateral prefrontal cortex and anteromedial
cingulate cortex were the most consistent ﬁndings. Parietal and/or
temporal cortex abnormalities were present in some. Findings
were mild in many, particularly early in the course, and relatively
symmetric cerebral cortical involvement was the rule.
Neuropathological considerations
All cases had TDP-43 pathology, and more than half also had
evidence of motor neuron degeneration and substantia nigra de-
generation. Overt clinical evidence of MND or parkinsonism was
not always associated with motor neuron or substantia nigra de-
generation, respectively. Cortical neuronal loss, gliosis and spon-
giosis was most prominent in frontal lobe, with less in parietal and
temporal lobes. Hippocampal sclerosis, which is common in
FTLD-TDP (Josephs and Dickson, 2007) was detected in less
than half the cases with c9FTD/ALS, possibly owing to the greater
frequency of FTLD-MND in this series, where it has been previ-
ously shown that hippocampal sclerosis is less frequent (Josephs
and Dickson, 2007). In an unselected autopsy series of c9FTD/
ALS, MND was less common, while hippocampal sclerosis was
more common than in this series (Murray et al., 2011). The pau-
city of prominent amnestic syndromes in the present series may be
accounted for partly by the low frequency of hippocampal
sclerosis.
The TDP-43 pathology was variable, with the majority being
type A. Type A (Mackenzie type 1) is characterized by many cor-
tical neuronal cytoplasmic inclusions and dystrophic neurites
often with intranuclear inclusions and widespread involvement of
subcortical areas, while type B (Mackenzie type 3) have many
neuronal cytoplasmic inclusions, but few dystrophic neurites and
more limited subcortical pathology (Josephs et al., 2009). These
ﬁndings contrast to what was expected from previously suggested
pathological correlates of c9FTD/ALS (Boxer et al., 2011;
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with type B (Mackenzie type 3) TDP-43 pathology. The explan-
ation for the heterogeneity in TDP-43 pathology remains to
be determined. It is of note that none of the cases had type C
(Mackenzie type 2) pathology, which is associated with promin-
ent cortical neuritic pathology with few cortical neuronal in-
clusions and clinically by the semantic subtype of primary
progressive aphasia, was also not a clinical syndrome found in
any patient in this series. The present ﬁndings contrast with de-
tection of at least a few cases with type C in an unselected aut-
opsy series of cases with the C9ORF72 mutation (Murray et al.,
2011).
It has been suggested that ubiquitin-positive (P62-positive) in-
clusions in cerebellar granule neurons are characteristic of c9FTD/
ALS (Al-Sarraj et al., 2011; Boxer et al., 2011; Murray et al.,
2011), and we were able to conﬁrm this except for three cases
in which such inclusions could not be detected. It has also been
suggested that in the hippocampus, cases with c9FTD/ALS have
neuronal inclusions that are disproportionately positive for ubiqui-
tin compared with TDP-43 (Al-Sarraj et al., 2011). We were able
to conﬁrm this ﬁnding. These are promising pathological features
that might one day prove to lead to a speciﬁc and sensitive bio-
marker for c9FTD/ALS when their protein composition is eventu-
ally determined.
Table 6 Key features of c9FTD/ALS due to the GGGGCC hexanucleotide repeat expansion in C9ORF72 compared with FTLD
due to mutations in the genes encoding MAPT and PGRN
Feature C9ORF72 MAPT PGRN
Demographic
Sex Male = Female Male = Female Male = Female
Age at onset, median (range) (years) 52 (33–72) 45 (25–65) 59 (35–85)
Survival, median (range) (years) 5 (1–17) 7 (2–25) 6 (3–15)
Inheritance
Inheritance pattern Autosomal dominant Autosomal dominant Autosomal dominant
Frequency of sporadic cases + + + +
Penetrance Probably high Almost 100% 90% by age 70
Anticipation suggested + + 0 +
Clinical
Behavioural variant FTD phenotype + + + + ++++ +++
ALS phenotype + + + + + +
FTD/ALS phenotype + + + + +
Parkinsonism + + + + + + +
PPA/corticobasal syndrome phenotype
a 0+ + +
Alzheimer-like phenotype
a +++
Neuropsychological
Impaired psychomotor speed + + + + ++++ ++++
Impaired complex attention/executive functioning + + + + ++++ ++++
Impaired word retrieval + + + + + + + + + +
Impaired episodic memory + + + + + +
Impaired gross visuospatial functioning + + +
Impaired confrontation naming + + + + + +
Impaired word reading 0 + +
MRI
Dorsolateral frontal/insular atrophy + + + + + + +
Parietal cortex atrophy + + + + +
Temporal cortex atrophy + + + + + +
Markedly focal or asymmetric atrophy 0 + + + +
White matter signal changes 0 + + +
SPECT/PET
Dorsomedial frontal/cingulate abnormal + + + + + + +
Parietal cortex abnormal + + + + +
Temporal cortex abnormal + + + + + +
Markedly focal or asymmetric ﬁndings 0 + + + +
Subcortical structures abnormal 0 + +
Neuropathology
Key proteinopathy TDP-43 tau TDP-43
TDP-43 type pathology A and B Not applicable A only
0 = not present;+ =infrequent;+ + occurred with some frequency; + + + moderately frequent; + + + + very frequent.
a Since only probands with the behavioural variant FTD, non-ﬂuent/agrammatic and semantic subtypes of primary progressive aphasia (PPA), and ALS were screened for
the GGGGCC expansion, the frequency of primary progressive aphasia, corticobasal syndrome, autosomal dominant, and other phenotypes with this mutation may be
higher than suggested here. Yet among those probands screened, and their affected relatives, the frequencies of these syndromes were low.
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post-mortem features and ﬁndings in
subjects with mutations in C9ORF72,
MAPT and PGRN
Comparing and contrasting the clinical, neuropsychological,
neuroimaging and neuropathological data between C9ORF72,
MAPT and PGRN features will provide insights for clinicians to bet-
ter target genetic testing (particularly for those with the behav-
ioural variant FTD phenotype), and also enlighten our
understanding of neurodegeneration associated with different mu-
tations. A summary of the known features associated with these
three mutations is shown in Table 6. Future analyses will likely
include comparisons such as those shown in Supplementary Figs
5 and 6.
Implications for research and future
clinical practice
These ﬁndings suggest that genetic testing for the hexanucleotide
repeat expansion in C9ORF72 should be considered in anyone
with the FTD and/or ALS phenotype and a positive family history
of dementia, parkinsonism or ALS. The presence of multiple
affected relatives, absence of primary progressive aphasia in any
affected relatives, symmetric and relatively mild frontal  parietal
and/or temporal atrophy on MRI, and FTLD-TDP pathology in any
relative should particularly raise suspicion of c9FTD/ALS. Clinical
genetic testing will surely be developed in the near future.
Considering that the frequency of the hexanucleotide repeat
expansion in C9ORF72 already exceeds the frequency of muta-
tions in the other known genes associated with familial FTD and/
or ALS, it is highly likely that a signiﬁcant proportion of individuals
with familial FTD and/or ALS without a mutation in the other
known genes will be found to harbour the hexanucleotide
repeat expansion in C9ORF72.
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